Loading…

Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study

The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to coll...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Endocrinology 2016-01, Vol.2016 (2016), p.401-405-146
Main Authors: Regidor, Pedro-Antonio, Schindler, Adolf Eduard
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143
cites cdi_FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143
container_end_page 405-146
container_issue 2016
container_start_page 401
container_title International Journal of Endocrinology
container_volume 2016
creator Regidor, Pedro-Antonio
Schindler, Adolf Eduard
description The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to collect data on ovulation and pregnancy rates in PCOS patients with infertility. In this observational study, 3602 infertile women used myoinositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone, and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. During this time 70% of these women had a restored ovulation, and 545 pregnancies were obtained. This means a pregnancy rate of 15.1% of all the myoinositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/ml to 43.3 ng/ml and progesterone from 2.1 ng/ml to 12.3 ng/ml ( p < 0.05 ) after 12 weeks of treatment. No relevant side effects were present among the patients. This study could show that a new treatment option for patients with a PCOS and infertility is available. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported by the use of metformin.
doi_str_mv 10.1155/2016/9537632
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e722859319ee4d1a9d6a724f86898f71</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A509160550</galeid><airiti_id>P20160919002_201612_201703160009_201703160009_401_405_146</airiti_id><doaj_id>oai_doaj_org_article_e722859319ee4d1a9d6a724f86898f71</doaj_id><sourcerecordid>A509160550</sourcerecordid><originalsourceid>FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143</originalsourceid><addsrcrecordid>eNqNkl1rFDEUhgdRbK3eeS0BQQTd9iQz-fJCWIrWQqWFVrwM2ZmTbspssk1mKv33Zndr2xUvZBjy9eTNOec9VfWawj6lnB8woOJA81qKmj2pdqlQcqLqhj-9n9dyp3qR8xWAEALo82qHSdEwpuVuNX6_jT7E7IfYE5uJJefWIbGhI9N-wBTs4G-QTJfLFG07Jz6QYY7kIqEdFhgGEh05Dg7T4HskZ4en5-RnLAefyJQcYVrYQE5nGdNN0YnB9uR8GLvbl9UzZ_uMr-7GverH1y8Xh98mJ6dHx4fTk4mVshkmM5hJSZlyTQNatR1wpuq25pqjoAiOccmcAnDQNdp1ra2psrpk3WnKGG3qvep4o9tFe2WWyS9sujXRerPeiOnS2BJ526NByZjiuqYasemo1Z2wkjVOCaWVk7Rofd5oLcfZAru2JJ9svyW6fRL83FzGG8Oh-FQC36ve3wmkeD1iHszC5xb73gaMYzZUMSqVBloX9O1f6FUcixd9NqwBKQQtBj5Ql7Yk4IOL5d12JWqmHEodgHMo1P4_qPJ1uPBtDOiKc9sX3j26MEfbD_Mc-3FlYN4GP27ANsWcE7r7YlAwq940q940d71Z8DePC3gP_2nGAnzYAHMfOvvL_6ccFgadfaAplPhW4Z1tAOuTH_xDCc9WOiULDcDWmnQ9SKjLNoDeXjRAy88NbUT9G6D6BlI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2407661764</pqid></control><display><type>article</type><title>Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study</title><source>Publicly Available Content Database</source><source>Wiley_OA刊</source><source>PubMed</source><creator>Regidor, Pedro-Antonio ; Schindler, Adolf Eduard</creator><contributor>Unfer, Vittorio ; Vittorio Unfer</contributor><creatorcontrib>Regidor, Pedro-Antonio ; Schindler, Adolf Eduard ; Unfer, Vittorio ; Vittorio Unfer</creatorcontrib><description>The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to collect data on ovulation and pregnancy rates in PCOS patients with infertility. In this observational study, 3602 infertile women used myoinositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone, and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. During this time 70% of these women had a restored ovulation, and 545 pregnancies were obtained. This means a pregnancy rate of 15.1% of all the myoinositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/ml to 43.3 ng/ml and progesterone from 2.1 ng/ml to 12.3 ng/ml ( p &lt; 0.05 ) after 12 weeks of treatment. No relevant side effects were present among the patients. This study could show that a new treatment option for patients with a PCOS and infertility is available. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported by the use of metformin.</description><identifier>ISSN: 1687-8337</identifier><identifier>EISSN: 1687-8345</identifier><identifier>DOI: 10.1155/2016/9537632</identifier><identifier>PMID: 27642297</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Acids ; Androgens ; Bioavailability ; Care and treatment ; Causes of ; Complications and side effects ; Dosage and administration ; Endocrinology ; Glucose ; Gynecology ; Infertility ; Infertility, Female ; Inositol ; Insulin resistance ; Menstruation ; Observational studies ; Ovulation ; Patient outcomes ; Pregnancy ; Questionnaires ; Stein-Leventhal syndrome ; Studies ; Testosterone ; Vitamin B</subject><ispartof>International Journal of Endocrinology, 2016-01, Vol.2016 (2016), p.401-405-146</ispartof><rights>Copyright © 2016 Pedro-Antonio Regidor and Adolf Eduard Schindler.</rights><rights>COPYRIGHT 2016 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2016 Pedro-Antonio Regidor and Adolf Eduard Schindler. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2016 P.-A. Regidor and A. E. Schindler. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143</citedby><cites>FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143</cites><orcidid>0000-0002-9551-2847</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2407661764/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2407661764?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25751,27922,27923,37010,37011,44588,53789,53791,74896</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27642297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Unfer, Vittorio</contributor><contributor>Vittorio Unfer</contributor><creatorcontrib>Regidor, Pedro-Antonio</creatorcontrib><creatorcontrib>Schindler, Adolf Eduard</creatorcontrib><title>Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study</title><title>International Journal of Endocrinology</title><addtitle>Int J Endocrinol</addtitle><description>The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to collect data on ovulation and pregnancy rates in PCOS patients with infertility. In this observational study, 3602 infertile women used myoinositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone, and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. During this time 70% of these women had a restored ovulation, and 545 pregnancies were obtained. This means a pregnancy rate of 15.1% of all the myoinositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/ml to 43.3 ng/ml and progesterone from 2.1 ng/ml to 12.3 ng/ml ( p &lt; 0.05 ) after 12 weeks of treatment. No relevant side effects were present among the patients. This study could show that a new treatment option for patients with a PCOS and infertility is available. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported by the use of metformin.</description><subject>Acids</subject><subject>Androgens</subject><subject>Bioavailability</subject><subject>Care and treatment</subject><subject>Causes of</subject><subject>Complications and side effects</subject><subject>Dosage and administration</subject><subject>Endocrinology</subject><subject>Glucose</subject><subject>Gynecology</subject><subject>Infertility</subject><subject>Infertility, Female</subject><subject>Inositol</subject><subject>Insulin resistance</subject><subject>Menstruation</subject><subject>Observational studies</subject><subject>Ovulation</subject><subject>Patient outcomes</subject><subject>Pregnancy</subject><subject>Questionnaires</subject><subject>Stein-Leventhal syndrome</subject><subject>Studies</subject><subject>Testosterone</subject><subject>Vitamin B</subject><issn>1687-8337</issn><issn>1687-8345</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl1rFDEUhgdRbK3eeS0BQQTd9iQz-fJCWIrWQqWFVrwM2ZmTbspssk1mKv33Zndr2xUvZBjy9eTNOec9VfWawj6lnB8woOJA81qKmj2pdqlQcqLqhj-9n9dyp3qR8xWAEALo82qHSdEwpuVuNX6_jT7E7IfYE5uJJefWIbGhI9N-wBTs4G-QTJfLFG07Jz6QYY7kIqEdFhgGEh05Dg7T4HskZ4en5-RnLAefyJQcYVrYQE5nGdNN0YnB9uR8GLvbl9UzZ_uMr-7GverH1y8Xh98mJ6dHx4fTk4mVshkmM5hJSZlyTQNatR1wpuq25pqjoAiOccmcAnDQNdp1ra2psrpk3WnKGG3qvep4o9tFe2WWyS9sujXRerPeiOnS2BJ526NByZjiuqYasemo1Z2wkjVOCaWVk7Rofd5oLcfZAru2JJ9svyW6fRL83FzGG8Oh-FQC36ve3wmkeD1iHszC5xb73gaMYzZUMSqVBloX9O1f6FUcixd9NqwBKQQtBj5Ql7Yk4IOL5d12JWqmHEodgHMo1P4_qPJ1uPBtDOiKc9sX3j26MEfbD_Mc-3FlYN4GP27ANsWcE7r7YlAwq940q940d71Z8DePC3gP_2nGAnzYAHMfOvvL_6ccFgadfaAplPhW4Z1tAOuTH_xDCc9WOiULDcDWmnQ9SKjLNoDeXjRAy88NbUT9G6D6BlI</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Regidor, Pedro-Antonio</creator><creator>Schindler, Adolf Eduard</creator><general>Hindawi Limiteds</general><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9551-2847</orcidid></search><sort><creationdate>20160101</creationdate><title>Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study</title><author>Regidor, Pedro-Antonio ; Schindler, Adolf Eduard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acids</topic><topic>Androgens</topic><topic>Bioavailability</topic><topic>Care and treatment</topic><topic>Causes of</topic><topic>Complications and side effects</topic><topic>Dosage and administration</topic><topic>Endocrinology</topic><topic>Glucose</topic><topic>Gynecology</topic><topic>Infertility</topic><topic>Infertility, Female</topic><topic>Inositol</topic><topic>Insulin resistance</topic><topic>Menstruation</topic><topic>Observational studies</topic><topic>Ovulation</topic><topic>Patient outcomes</topic><topic>Pregnancy</topic><topic>Questionnaires</topic><topic>Stein-Leventhal syndrome</topic><topic>Studies</topic><topic>Testosterone</topic><topic>Vitamin B</topic><toplevel>online_resources</toplevel><creatorcontrib>Regidor, Pedro-Antonio</creatorcontrib><creatorcontrib>Schindler, Adolf Eduard</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International Journal of Endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Regidor, Pedro-Antonio</au><au>Schindler, Adolf Eduard</au><au>Unfer, Vittorio</au><au>Vittorio Unfer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study</atitle><jtitle>International Journal of Endocrinology</jtitle><addtitle>Int J Endocrinol</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>2016</volume><issue>2016</issue><spage>401</spage><epage>405-146</epage><pages>401-405-146</pages><issn>1687-8337</issn><eissn>1687-8345</eissn><abstract>The use of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with a polycystic ovary syndrome (PCOS). Using a questionnaire an observational study was performed under German gynecologists to collect data on ovulation and pregnancy rates in PCOS patients with infertility. In this observational study, 3602 infertile women used myoinositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myoinositol + 2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone, and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. During this time 70% of these women had a restored ovulation, and 545 pregnancies were obtained. This means a pregnancy rate of 15.1% of all the myoinositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/ml to 43.3 ng/ml and progesterone from 2.1 ng/ml to 12.3 ng/ml ( p &lt; 0.05 ) after 12 weeks of treatment. No relevant side effects were present among the patients. This study could show that a new treatment option for patients with a PCOS and infertility is available. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported by the use of metformin.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>27642297</pmid><doi>10.1155/2016/9537632</doi><orcidid>https://orcid.org/0000-0002-9551-2847</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1687-8337
ispartof International Journal of Endocrinology, 2016-01, Vol.2016 (2016), p.401-405-146
issn 1687-8337
1687-8345
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e722859319ee4d1a9d6a724f86898f71
source Publicly Available Content Database; Wiley_OA刊; PubMed
subjects Acids
Androgens
Bioavailability
Care and treatment
Causes of
Complications and side effects
Dosage and administration
Endocrinology
Glucose
Gynecology
Infertility
Infertility, Female
Inositol
Insulin resistance
Menstruation
Observational studies
Ovulation
Patient outcomes
Pregnancy
Questionnaires
Stein-Leventhal syndrome
Studies
Testosterone
Vitamin B
title Myoinositol as a Safe and Alternative Approach in the Treatment of Infertile PCOS Women: A German Observational Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A03%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myoinositol%20as%20a%20Safe%20and%20Alternative%20Approach%20in%20the%20Treatment%20of%20Infertile%20PCOS%20Women:%20A%20German%20Observational%20Study&rft.jtitle=International%20Journal%20of%20Endocrinology&rft.au=Regidor,%20Pedro-Antonio&rft.date=2016-01-01&rft.volume=2016&rft.issue=2016&rft.spage=401&rft.epage=405-146&rft.pages=401-405-146&rft.issn=1687-8337&rft.eissn=1687-8345&rft_id=info:doi/10.1155/2016/9537632&rft_dat=%3Cgale_doaj_%3EA509160550%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a774t-b0b77128f44098cd05283c3595e61e0f2572f800f0d49fdca318a9168d9122143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2407661764&rft_id=info:pmid/27642297&rft_galeid=A509160550&rft_airiti_id=P20160919002_201612_201703160009_201703160009_401_405_146&rfr_iscdi=true